ISSN 2306-5559 (print)
ISSN 2410-938X (online)
ISSN 2410-938X (online)
Отсутсвует
Иинтервенционный кардиолог, аритмолог; PhD докторант кафедры политики и организации здравоохранения; старший преподователь кафедры клинических дисциплин
1. Anderson J., Adams C., Antman E. et al. et al. ACC/AHA 2007 guidelines for the management of patients with unstable angi-na/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am CollCardiol. 2007; 50: el—e157.2. Demirelli S., Karakelleoglu S., Gundogdu F. et al. The impact of trimetazidine treatment on left ventricular functions and plasma brain natriuretic peptide levels in patients with non-ST segment elevation myocardial infarction undergoing percutaneous coronary intervention. Korean Circ J. 2013; 43: 462-467.3. Di Napoli P., Taccardi A., Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart. 2005; 91: 161-165.4. Fragasso G., Perseghin G., De Cobelli F. et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J. 2006; 27: 942-948.5. Zhou X., Chen J. Is treatment with trimetazidine beneficial in patients with chronic heart failure? PLoS One. 2014; 9: e94660.6. Gao D., Ning N., Niu X. et al. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 2011;97: 278-286.7. Zhang Y., Ma X.-J., Shi D.-Z. Effect of Trimetazidine in Patients Undergoing Percutaneous Coronary Intervention: A Me-la-Analysis. PLoS ONE 10(9): e0137775. doi: 10.1371/jour-nal.pone.0137775.8. Zhang N., Lei J., Liu Q. et al. The effectiveness of preopera-tivetrimetazidine on myocardial preservation in coronary artery bypass graft patients: a systematic review and meta-analysis. Cardiology, 2015; 131: 86-96.9. Nikol S., Huehns T., Hofling B. Molecular biology and post-angioplasty restenosis. Atherosclerosis 1996; 123: 17-31.10. Dangas G., Claessen B., Caixeta A. et al, In-stent restenosis in the drug-eluting stent era. 1 Am Coll Cardiol 2010; 56:11. Tsigkas G., Karantalis V., Hahalis G., Alexopoulos D. Stent re-stenosis, pathophysiology and treatment options: a 2010 update. Hellenic J Cardiol 2011; 52: 149-57.12. Kearney M., Pieczek A., Haley L. et a Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation 1997; 95: 1998-200213. Thanyasiri P., Kathir K., Celermajer D., Adams M. Endothelial dysfunction and restenosis following percutaneous coronary intervention. Int J Cardiol 2007; 119: 362-7.14. Lafont A., Durand E., Samuel J. et al. Endothelial dysfunction and collagen accumulation: two independent factors for restenosis and constrictive remodeling after experimental angioplasty. Circulation 1999; 100: 1109-15.15. Losordo D., Isner J., Diaz-Sandoval L. Endothelial recovery: the next target in restenosis prevention. Circulation 2003; 107:2635-7.16. Hedman M., Hartikainen J., Syvanne M. et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003; 107: 2677-83.17. Serruys P., de Jaegere P., Kiemeneij F. et al. A comparison of balloon-expandablestent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331: 489-95.18. Fischman D., Leon M., Baim D. et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331: 496-501.19. Zahn R., Hamm C., Schneider S. et al. Incidence and predictors of target vessel revascularization and clinical event rates of the sirolimus-eluting coronary stent (results from the prospective multicenter German Cypher Stent Registry). Am J Cardiol 2005; 95: 1302-8.20. Mauri L., Silbaugh T., Wolf R. et al. Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachus-etts. Circulation 2008; 118: 1817-27.21. Lemos P., Serruys P., van Domburg R. et al. Unrestricted utilization of sirolimuseluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RES-EARCH) registry. Circulation 2004; 109: 190-5.22. Stolker J., Kennedy K., Lindsey J. et al. Predicting restenosis of drug-eluting stents placed in real-world clinical practice: derivation and validation of a risk model from the EVENT registry. Circ Cardiovase Interv 2010; 3: 327-34.23. Belardinelli R., Solenghi M., Volpe L., Purcaro A. Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect. Eur Heart J 2007; 28: 1102-8.24. Di Napoli P., Chierchia S., Taccardi A. et al. Trimetazidine improves post-ischemic recovery by preserving endothelial nitric oxide synthase expression in isolated working rat hearts. Nitric Oxide 2007; 16: 228-36.25. Chen J., Zhou S., Jin J. Chronic treatment with trimetazidine after discharge reduces the incidence of restenosis in patients who received coronary stent implantation: a 1-year prospective follow-up study. Int J Cardiol. 2014 Jul 1; 174 (3): 634-9.